Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Flucytosine Conversion Enzyme FCU1 (FCU1)
- Target
- FCU1
- Molecular classification
- Enzyme, Fusion Protein, Cytosine deaminase, Uracil phosphoribosyltransferase
01
Overview
The FCU1 enzyme is a bifunctional fusion protein comprised of cytosine deaminase and uracil phosphoribosyltransferase activities. It converts the prodrug flucytosine (5-FC) into the cytotoxic chemotherapeutic agent fluorouracil (5-FU) within target cells. This conversion is a key component of gene-directed enzyme prodrug therapy (GDEPT) strategies for cancer treatment, allowing for targeted tumor cell killing while minimizing systemic toxicity associated with direct fluorouracil administration.
- Other names
- 5-Fluorocytosine deaminase/uracil phosphoribosyltransferaseCytosine deaminase/uracil phosphoribosyltransferase fusion protein
02
Mechanism of action
Enzymatic conversion of flucytosine to fluorouracil, followed by phosphorylation into cytotoxic nucleotide analogs that inhibit DNA and RNA synthesis.
03
Biological functions
Prodrug activationFluorouracil synthesisDNA/RNA synthesis inhibition (indirect)
04
Disease associations
Cancer
05
Safety considerations
Potential systemic toxicity due to off-target expression or leakage.Induction of converting enzymes in non-target tissues with chronic exposure.
06
Interacting drugs
Flucytosine
1 more in the full profile.
Beyond the preview
Go deeper on Flucytosine Conversion Enzyme FCU1 (FCU1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flucytosine Conversion Enzyme FCU1 (FCU1).